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ABSTRACT OF DISSERTATION

CIS- AND TRANS-ACTIVATION OF HORMONE RECEPTORS:
THE LH RECEPTOR
The Luteinizing hormone receptor (LHR) belongs to the G protein-coupled receptor family, as
do the other glycoprotein hormone receptors for FSH, TSH, and CG. The LHR comprises two
halves of ~350 amino acids: an extracellular hormone binding exodomain and a seven
transmembrane-spanning endodomain responsible for signal generation. Hormone binds to the
exodomain with high affinity, and the resulting conformational changes in the
hormone/exodomain complex modulate the endodomain to generate hormone signals. Hormone
binding to an LHR produces hormonal signals (cis-activation), but it is not known whether a
liganded LHR could activate other unoccupied LHRs (trans-activation). The LHR activates both
adenylyl cyclase and phospholipase Cβ. This dissertation shows that trans-activation of the LHR
leads to the activation of adenylyl cyclase to induce cAMP but not to the activation of
phospholipase Cβ to induce the inositol phosphate signaling. Trans-activation offers a
mechanism of signal amplification at the receptor level and also provides a mechanism of
multiple signal generation for a liganded LHR to cis-activate phospholipase Cβ and transactivate adenylyl cyclase. Also coexpression of Gi2 with a constitutively activating LHR
(Asp578Gly), the most common mutation of male-limited precocious puberty, shows that Gi2
could completely inhibit cAMP induction by the LHR mutant. Experiments using the carboxyl
terminal region of G protein α subunits demonstrate that LHR has overlapping binding sites for
Gα subunits Gs and Gi2.
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Chapter 1

Introduction

Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)
LH, FSH, TSH, and CG belong to the glycoprotein hormone family (1). These hormones are
heterodimers of α and β subunits; sharing a common α subunit consisting of 92 amino acids (1).
Hormone-specific β subunits vary in size; 121 amino acids are found in the LHβ while hCGβ has
145 amino acids (1) (Figure 1.1). LH, FSH, and TSH are released from the anterior pituitary, and
CG originates from the placenta during pregnancy (1). LH and CG bind to the same receptor on
granulosa cells, known as the LH/CG receptor or the LHR (2).
FSH elicits the primary signal for starting preovulatory follicular development (3). It takes 10-12
days of sustained stimulation by FSH for a ~5 mm follicle to attain a full preovulatory diameter
of ≥ 20 mm; during this time the number of its granulosa cells increases 5 or 6 fold to reach over
50 million (4), while the number of FSHRs in each granulosa cell increases 4 to 5 fold (5). FSH
directly stimulates proliferation of granulosa cells and induces the LH-responsive mechanisms in
cells that will sustain steroid secretion by the preovulatory follicle and, after ovulation, the
corpus luteum (3). FSH binds to the FSHR in granulosa cells, inducing mRNA expression of
FSH-responsive genes such as LHR, steroidogenic enzyme P450 aromatase, and regulatory
peptides such as inhibin subunits and follistatin (6).
LH mediates the secretion of steroid hormones by the preovulatory follicles and corpus luteum
(3). Estrogen secretion by the follicles increases during the second half of the follicular phase
when the frequency of pulsatile LH discharge by the pituitary increases and FSH secretion
decreases (3). During this stage of development, granulosa cells express LHR, and tonic levels of
LH are able to directly stimulate steroidogenic enzyme systems preinduced by FSH (3). LH acts
through the LHR on theca cells and mature granulosa cells to induce mRNA expression of LHresponsive genes such as those responsible for precursor-cholesterol uptake and sustains high
steroidogenic enzyme activity (6). An ovulation-inducing dose of LH is released by the pituitary
gland at mid-menstrual cycle. This terminates proliferation of granulosa cells and simultaneously
initiates rupture of the ovulatory follicle and onset of luteal progesterone secretion. If pregnancy
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occurs, the functional lifespan of the corpus luteum is extended by choriogonadotropin acting
through the same LH/CG receptor (3).
The LH Receptor
These cellular responses of LH, FSH, and CG are mediated by their cognate receptor on the cell
surface. The LHR and the FSHR belong to the G protein-coupled receptor family, the largest
known receptor family in the human genome (7). These receptors consist of two halves of ~350
amino acids: the N-terminal half (exodomain) and the membrane-associated C-terminal half
(endodomain) (7) (Figure 1.2). The exodomain consists of 10 exons and is mainly responsible for
hormone binding (8, 9). The 11th exon encodes the endodomain which generates hormone
signals (8, 9). The endodomain is equivalent in size to most of the other GPCRs which do not
carry a long exodomain (7). The endodomain comprises seven transmembrane (TM) helices,
three extracellular connecting loops (exoloops), three intracellular connecting loops (cytoloops),
and a C-terminal tail (7).
The LHRs are expressed in the Leydig cells in males, and in the theca cells and the mature
granulosa cells in females. The expression of LHRs in the later developmental stage of the
granulosa cells requires the continual presence of FSH (10, 11), and this induction of LHR by
FSH is mediated by cAMP (12, 13).
A study of hCG binding to ovarian receptors showed the Hill coefficient of 0.9 for LH and 1.1
for hCG, suggesting binding of 1 mol of gonadotropin/mol of receptor (14). The number of
LHRs expressed in Leydig cells or in ovarian granulosa cells are in the range of 6,000 – 20,000
receptor/cell (15-17). However, studies suggest that only 1-3% of receptor occupancy is enough
to induce maximal steroidogenesis in Leydig cells and granulosa cells (15, 18), suggesting the
most likely function of excess receptors is to take up and clean circulating gonadotropins.
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Hormone Binding and Receptor Activation
Exodomain of the LHR binds to hCG with high affinity (9, 19). Many groups have revealed
important regions on the LHR for hormone binding. It is now known that there are three
important regions in the exodomain of the LHR for hormone binding: the N-terminal cysteinerich region, the LRR region, and the C-terminal cysteine-rich area (the hinge region) (Figure 1.3).
A study using synthetic peptides identified four hormone binding regions of the LHR: Arg21Pro38 (near the N-terminus), Arg102-Thr115 (LRR 4), Tyr253-Phe272 (hinge region), and Lys573Lys583 (exoloop 3) (20). Further study on the N-terminal region of the LHR shows that crucial
amino acids in the region for hormone binding are Leu20, Cys22, and Gly24 (21). It was also
demonstrated that both the α and β subunits of hCG contact the N-terminal region of the LHR
(22).
The Leu-rich repeat (LRR) region, crucial for hormone binding, is located in the center of the
exodomain and has nine repeats, each of which are 20-28 amino acids long. Based on the crystal
structure of LRR proteins (23), up to 15 LRRs form a non globular horseshoe-shaped structure
with an inner lining of curved β strands and an outer lining of helices (24). The LRR 1-6 of the
LHR were shown to be important for hormone binding (25), and our group further identified that
the upstream LRR 2 and 4 and downstream LRR 7 and 8 were shown also important for
hormone binding (26, 27). Affinity labeling study of the LRR 4 of the LHR showed that the Nterminal region of LRR 4 interacts with hCG, preferentially the hCG α subunit, and that
hCG/LRR 4 complex interacts with exoloop 2 of the endodomain (28).
In addition to the N-terminal and the LRR regions, the hinge region (Thr250-Gln268) also binds to
hCG with affinity, preferentially to hCGα (29). The interaction between hormone and the hinge
region is inhibited by exoloop 2 of the endodomain but not by exoloops 1 and 3, suggesting an
intimate relationship between Thr250-Gln268, exoloop 2, and hCG (29). This hinge region is
elucidated not only important for hormone binding but also for signal generation. When S255 was
mutated to Ala, the mutant receptor showed 4-7 fold increased basal cAMP (30).
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Hormone binding occurs mainly in the exodomain of the LHR with high affinity, but there is
evidence that hormone also contacts to the endodomain with low affinity and modulates
hormone signals. The N-terminal exodomain-truncated LHR binds to hCG with low affinity and
produces cAMP at high hormone concentrations (9, 31), suggesting that there is a secondary
contact of hormone/exodomain complex to the endodomain upon hormone binding, thus
generating hormone signals from the endodomain of the receptor. The inhibition of hormone
binding by a synthetic peptide of the exoloop 3 (Lys573-Lys583) suggests that exoloop 3 is one of
the multiple hormone contact sites in the endodomain of the LHR (20). Our group showed the
first physical evidence of hormone binding to the endodomain with a photoaffinity labeling of
FSH by the exoloop 3 peptide of the FSHR (32).
Hormone binding to the exodomain is also constrained by the endodomain of the LHR.
Endodomain-truncated LHR showed twice as high hormone binding affinity (33). Site-directed
mutagenesis studies suggest that mutations in the exoloops 2 and 3 modulate hormone binding to
the exodomain (33, 34). There are also many mutations located in the TM region abolishing
hormone binding (35). Our group demonstrated that hormone binding to the hinge region
(Thr250-Gln268) is inhibited by the exoloop 2 peptide (29). Hsueh’s group showed that when
Ser255 in the hinge region is mutated, the LHR shows constitutive activity (30). When the hinge
region including Ser255 and the exoloop 2 of the fly LGR was replaced by the human LHR
counterpart, the chimeric receptor had reduced constitutive activity (36), demonstrating that the
hinge region and the exoloop 2 of the human LHR keep the receptor in an inactivate
conformation and that the mutation in Ser255 disrupts the conformation leading to constitutive
activation (30). The interaction between the hinge region and the exoloop 2 was also
demonstrated in the H3 relaxin receptor, another Leu-rich repeat-containing G protein-coupled
receptor (37).
It has been shown that hormone binding to the LHR is constrained by the endodomain. There is
evidence in the TSH receptor that the exodomain also constrains the endodomain activity. When
the exodomain of the TSH receptor was removed, the endodomain of the TSH receptor showed
4-7 fold higher basal level activity in the absence of hormone (38). Serial N-terminal truncation
of the TSH receptor showed that as the truncation proceeds towards Ser281 (corresponding to
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Ser255 in the LHR), the truncated receptor showed increased constitutive activity in the absence
of hormone (39). This constitutive activity of the endodomain was also assumed for the LHR,
but there is evidence that the mechanism of receptor activation of the LHR is different from that
of the TSH receptor. First, no constitutive activity of the LHR endodomain has been reported (31,
40, 41). Second, studies indicate that Gly109 in the LRR 4 works as an activator for signal
generation (27) and the exodomain itself is also required for the constitutive activity of LHRS255A
(41).
Reconstitution of a functional LHR by coexpression of its split exodomain and endodomain
shows evidence of sufficient interactions between the exodomain and the endodomain
responsible for receptor activation and signal generation (40). The interaction between the
exodomain and the endodomain were further investigated in this dissertation with definedfunction LHR mutants (42, 43).
Taken together, hormone binding to the LHR leads to conformational changes of the
hormone/exodomain complex and elicits hormone signals from the endodomain of the receptor
(24). Hormone signals are considered to be generated from the hormone/receptor interface and
the hormone/receptor conformational changes are thought to propagate through the TM to the
cytoplasmic part of the receptor (24). When signals reach cytoloop 3 and the C-terminal tail, G
protein α subunit is activated and released from the βγ subunits, leading to the activation of
effector molecules (24). The LHR activates adenylyl cyclase and phospholipase Cβ to induce
cAMP and inositol phosphate signaling, respectively (17). Gs, upon release from the LHR, is
responsible for the activation of adenylyl cyclase. Gi2 or βγ subunit released from Gi2 is known to
activate phospholipase Cβ (44). cAMP binds to regulatory subunits of the protein kinase A and
activates intracellular signaling pathways, including mitogen-activated kinase pathways. Diacyl
glycerol and IP3 generated by phospholipase Cβ also activates protein kinase C pathway and
Ca2+ mobilization in the cell, respectively. These molecular activations of signaling molecules
invoke cellular responses mediated by the LHR.
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Mutations of the LHR
Many important findings on the structure-function relationship of the LHR have been revealed
with the findings of mutations in patients or through mutagenesis studies. The discovery of LHR
mutation Lys583 to either Arg or Ala played an important role in understanding the relationship of
hormone binding, signal generation, and signal divergence. Lys583 is located in the junction of
TM7 and exoloop 3. Exoloop 3 is the shortest exoloop, consisting of 11 amino acids (exoloop 1
has 21 amino acids, and exoloop 2 has 20 amino acids). When Lys583 was mutated to Arg, the
mutant LHRK583R maintained normal cell surface expression and hormone binding affinity but
failed to produce cAMP and inositol phosphate signaling (45, 46). Though it was suggested a
decade earlier that receptor activation is separable from hormone binding (9), LHRK583R is the
first mutation found in the LHR which is crucial for receptor activation but not for hormone
binding (45). Because of the short exoloop 3 size, mutation in the exoloop 3, including the
LHRK583R, is considered to be more sensitive compared to mutations in exoloops 1 and 2.
Whn Lys583 was mutated to Ala, the mutant receptor did not produce cAMP as LHRK583R did not,
but it produced inositol phosphate signaling similar to wild type LHR (46). This suggests that
there are two distinct transmembrane signal conductors for cAMP and inositol phosphate signals
in the LHR (46). The selectivity of hormone signals by the mutation of Lys583 to Arg or Ala
further suggests that hormone signals generated from conformational changes in the
hormone/exodomain complex are diverged in the exoloop areas.
Mutations in the LHR or the FSHR cause disorders related to reproduction and secondary sexual
characteristics including infertility and precocious puberty (35, 47). 15-16 percent of the human
population are infertile, affecting 80 million people worldwide with 5 million in the Unites States
alone (48, 49). While there are other factors affecting infertility, mutations in the LHR and FSHR
cause infertility in men and women, and mutations in the LHR have been found more frequently
than those in FSHRs. Inactivating mutations of the LHR cause Leydig cell hypoplasia with
complete female external genitalia in the male, whereas they cause menstrual disorders, cystic
ovaries, and infertility in the females. Activating mutations of the LHR have only been found in
males causing precocious puberty with onset at the age of 3 to 5, thus termed male-limited
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precocious puberty. In females, however, activating mutations of the LHRs are asymptomatic
and do not cause any phenotypes.
Inactivating mutations are found both in the exo- and endodomain of the LHR, whereas
activating mutations are mainly found in the endodomain (35). Several inactivating mutations
were found in the exodomain, including an insertion of 11 amino acids in the N-terminal region,
deletion of the exon 8, and point mutations at Cys133 and Asn291 (35, 50). These do not result in
production of cAMP due to their failure to bind hormone. Inactivating mutations in the
endodomain mostly located in the TM5 to 7 also prevent hormone binding (35). There is no
direct evidence yet as to how TM mutations affect hormone binding, but these endodomain
mutations further support the evidence that hormone binding is constrained by the endodomain
(33, 34). Most inactivating mutations are either from non-hormone binding or from reduced cell
surface expression, and there is no report yet on a clinical mutation with normal hormone
binding affinity but with impaired signaling like that of LHRK583R.
Activating LHR mutations were found in every TM except TM3 and 7, with the majority of
activating mutations located in TM6, known as the “hot spot” of activating LHR mutations
(Figure 1.6). Upon ligand binding to the rhodopsin and the β2-adrenergic receptors, there is a
movement of the cytoplasmic end of TM6 away from TM3 leading to conformational changes in
TMs and cytoloops (51). Mutations in the TM6 hot spot area of the LHR cause constitutive
receptor activation, not only by the disruption of interhelical bonds stabilizing the inactivate state,
but also by the formation of new bonds that can stabilize an active state of the receptor (52). It
was shown that the Asp578Gly mutation, the most frequently found activating LHR mutation,
serves as a hydrogen bond acceptor. It is this, rather than a hydrogen bond donor, that is
important for stabilizing the inactivate state of the LHR (53).
Each human cell contains two copies of each chromosome, one inherited from the mother and
one from the father, thus called homologous chromosomes. Thus, even if there is a mutation in a
gene in one allele, the other allele of the same gene can complement the function of the mutated
allele. However, in some patients both copies of a gene were found to be mutated. Three cases of
mutations of the LHR gene in both alleles have been reported (54-56). The finding of these
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compound heterozygotes provided the grounds of this dissertation to study the relationship of
two defective heterozygous LHRs, especially the relationship between the exodomain of one
receptor and the endodomain of the other receptor. It is of particular interest because some
patients may have compound heterozygous LHR mutations, but the patients may not be infertile
due to successful rescuing of signaling by complementation of two defective functions: LHR-hCG
and LHR+hCG/-cAMP (Figure 1.8). The LHR gene is located on the chromosome 2 spanning 2p2126 (57).
The first compound heterozygote of an LHR was reported from a patient with Leydig cell
hypoplasia (54). The patient had three mutations: deletion of exon 8 (exodomain, LHR) in one
allele and Asn291Ser (exodomain) and Ser616Tyr (TM7) in the other allele. Hormone binding
assays with the exon 8 deletion showed failure of cell surface expression of the receptor.
Transfection studies with the Asn291Ser/Ser616Tyr double mutations showed reduced cell surface
expression and signal generation. Another case of compound heterozygous mutation was found
in a family with two 46, XY children affected with Leydig cell hypoplasia (55). The first
mutation, Cys545Stop in the TM5, had impaired cell surface expression and cAMP generation,
and the second mutation, insertion of 11 amino acids in the exon 1, had reduced cAMP induction.
The third case of compound heterozygote resulting in complete Leydig cell hypoplasia was
reported with two mutations of Cys343Ser in the hinge region of the exodomain and Cys543Arg in
the TM5 (56). Both mutant LHRs had normal protein level in the cytoplasm by Western blotting
study, but cell surface expression of the mutant receptors was completely impaired, implicating
that translocation is halted at the endoplasmic reticulum level blocking further processing to the
cell surface. In addition to the LHR mutations, three cases of compound heterozygous FSHR
mutations have been reported (58-60).
Goal of Dissertation
This dissertation has three goals. The first goal is to elucidate whether the LHR, upon hormone
binding, activates other unoccupied LHRs inter-molecularly for the rescue of cAMP signaling
(trans-activation) (Figure 1.8). This is particularly important considering that there are patients
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with compound heterozygotes of LHRs (54-56) or FSHRs (58-60), and the relationship between
the compound heterozygous LHR or FSHR is unknown.
Second, I want to find whether or not the LHR also activates other unoccupied LHRs for inositol
phosphate signaling as well as cAMP signaling. This is of interest because the LHR activates
both cAMP and inositol phosphate signaling, but the activation requires different hormone
concentrations and mechanisms.
Finally, this dissertation will discuss whether or not a single LHR activates both Gs and Gi2
molecules simultaneously or individually. Although the LHR generates both cAMP and inositol
phosphate signaling, their temporal relationship has not yet been studied.

Copyright © ChangWoo Lee 2003
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Figure 1.1 Crystal structure of hCG. hCG α (92 amino acids) is shown in red, and hCG β
(145 amino acids) in green. The seat belt region of hCG β is shown in blue, wrapping around the
α subunit stabilizing the heterodimers.
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Figure 1.2 Schematic diagram of the LHR. The N-terminal exodomain consists of ~350
amino acids and binds to hormone with high affinity. An equal-sized endodomain is membraneassociated and is responsible for signal generation.
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Figure 1.3 Important regions of the LHR for hormone binding. Hormone binds to the Nterminal cysteine-rich region, Leu-rich repeat (LRR) region, and the C-terminal hinge region.
Adapted from Nakabayashi et al. (2000) J Biol Chem 275, 30264-71 (30). S277 in the human
LHR corresponds to S255 in the rat LHR.

12

Figure 1.4 Side and top view of the LHR endodomain. TMs are located counterclockwise
and connected by exoloops and cytoloops. Cytoloops are not shown in the figure.
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Figure 1.5 Receptor activation and signal generation of the LHR. Hormone binding to the
exodomain undergoes conformational changes in the hormone/exodomain complex and
modulates the endodomain to generate signals. The LHR activates adenylyl cyclase and
phospholipase Cβ to induce cAMP and inositol phosphates, respectively.
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Figure 1.6 Mutations of the human LHR. Amino acids relevant for hormone binding,
inactivating, and activating mutations are denoted with different colors. Due to a different
numbering custom between human and rat LHR, subtract 22 to find the corresponding amino
acid in the rat LHR from the above sequence.
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Figure 1.7 Defined-function mutants in the LHR used in this dissertation to access
receptor-receptor interactions. L20A, C22A, I55A, and I80A (LHR-hCG) are located in the
exodomain. P479A and P479G (LHR-hCG) are located in the TM4. K583R is located in the junction
of exoloop 3 and the TM7 (LHR+hCG/-cAMP).
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Figure 1.8 Cis-activation and trans-activation of LHRs. A. Domain structure of LHR
showing the exodomain where the ligand binds and the endodomain where the hormone signal is
generated. B. Cis- and trans-activation of monomeric LHRs. The ligand is shown in red. C. Cisand trans-activation of dimeric LHRs. D. Trans-activation of a mutant LHR that is defective in
ligand binding in the exodomain (blue) but is capable of generating a hormone signal in the
endodomain (gray) (LHR-hCG/+cAMP) by a mutant LHR that is capable of binding ligand in the
exodomain (gray) but incapable of generating a hormone signal in the endodomain (blue)
(LHR+hCG/-cAMP).
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Chapter 2

Trans-activation of the LHR for cAMP Signaling

Introduction
The luteinizing hormone receptor (LHR) plays a crucial role in the development of the gonads in
both sexes and ovulation in females. Defective mutations of the receptor often cause infertility
(61). Gain of function mutations are generally dominant, whereas loss of function mutations are
recessive. The genetic prediction of mutations is not straightforward, because the effects of some
mutations are partial and some patients are defective heterozygotes. For example, there are
patients with two defective heterozygous LHR mutations (54-56) and the precise relationship of
two mutant receptors in a patient is unclear. This is particularly relevant for LHR, which has two
distinct domains, one for hormone binding and the other for signal generation (7, 62, 63).
We wondered about the relationship between the two alleles as to whether they would be
dependent on or independent of each other. Particularly, there is the intriguing possibility that
two heterozygous mutants, one defective in hormone binding and the other with normal hormone
binding but defective signal generation, might interact with each other to rescue hormone action
(Figure 1.8). Obviously, this would require the novel intermolecular interaction of the exodomain
of one LHR with the endodomain of another LHR. Although it has never been described, it
would have significant impact on the interpretation of receptor genetics and provide new insights
into clinical treatments. To test this hypothesis, various heterozygous defective LHRs were
paired and tested for their functional rescue were coexpressed.
Materials and Methods
Mutagenesis
Mutant rat LHR cDNAs were prepared in a pSELECT vector using the non-polymerase chain
reaction-based Altered Sites Mutagenesis System (Promega). The multiple cloning site of the
vector was cut with XbaI and BamHI, and then uni-directionally ligated with full-length rat LHR
cDNA. Single strand DNA was prepared, and mutagenesis was performed according to the
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manufacturer’s instruction. Oligonucleotides were purchased from Biosource. Vectors containing
mutant LHR constructs were selected by ampicillin screening. After confirming mutations by
sequencing, the mutant cDNAs were subcloned into the BamHI and XbaI sites of
pcDNA3/neomycin (Invitrogen), a eukaryotic expression vector.
Plasmid Purification
Wild type or mutant LHR cDNAs prepared through mutagenesis was transformed into TOP10
competent cells (Invitrogen) using Gene Pulser II electroporator (Bio-Rad) and plated onto
LB/ampicillin (125 µg/ml) plates. LHR plasmid DNAs were purified by CsCl/ethidium bromide
equilibrium centrifugation or by large-scale plasmid kits (QIAGEN and Bio-Rad).
Transfection
Varying concentrations of plasmids were transfected into human embryonic kidney (HEK)
293 cells by the calcium phosphate method (64). Briefly, 6-24 µg of plasmid DNA was added
into 1.7 ml tube containing 250 µl of 0.25 M CaCl2 followed by 250 µl of 2X BES. The mixture
was vortexed shortly, incubated for 8-12 min at room temperature, and transferred into T25 flasks
(Corning) of cultured cells drop by drop. Transiently transfected cells were assayed 60-72 h after
transfection. Stable cell lines were established in minimum essential medium (MEM) containing
8% horse serum and 500 µg/ml G-418. All assays were carried out in duplicate and repeated
three to four times (n = 6-8). Means and standard deviations were calculated.
cAMP Assay
Cells were washed twice with MEM and incubated in the medium containing
isobutylmethylxanthine (0.1 mg/ml) for 15 min. Increasing concentrations of hCG were then
added, and the incubation was continued for 45 min at 37 °C. After the medium was removed,
the cells were rinsed once with fresh medium without isobutylmethylxanthine, lysed in 70%
ethanol, freeze-thawed in liquid nitrogen, and scraped. After pelleting cell debris at 16,000 × g
for 10 min at 4 °C, the supernatant was collected, dried under vacuum, and resuspended in 10 µl
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of the cAMP assay buffer provided by the 125I-cAMP assay kit (Amersham Biosciences). cAMP
concentrations were determined following the manufacturer's instruction and validated for use in
our laboratory.
Iodination of Hormones and Antibodies
hCG (CR-127) and human FSH (AFP-7298A), provided by the National Hormone and Pituitary
Program, were radio-iodinated as described previously (65). Briefly, 50 µl of phosphate-buffered
saline (pH 7.4) was added to 3 to 8 µg of hCG. To this solution were added 7 µl of chloramine-T
(0.33 mg/ml) and 1 mCi (1 Ci = 3.7 × 1010 becquerels) of sodium [125I]iodide in 10 µl of 0.1 M
NaOH; 20 sec later, iodination was stopped by addition of 7 µl of sodium metabisulfite (0.66
mg/ml). The iodinated hCG (125I-hCG) was immediately fractionated on a Sephadex G-50
(superfine) column (0.6 × 15 cm). Radio-activity of each fraction was measured in a gamma
counter (Beckman) and the fraction of highest radio-activity was kept at 4 °C for hormone
binding assays. Specific activity of 125I-hCG was in the range of 60,000 - 80,000 cpm/ng of hCG.
Hormone Binding Assay
Cells were washed twice with medium, MEM with 20 mM of HEPES, pH 7.4 and 0.1 g/100 ml
of bovine serum albumin. Cells were assayed for 125I-hormone (150,000 cpm) binding in the
presence of increasing concentrations of non-radioactive hormone for 90 min at 37 °C. Cells
were washed twice with medium, solubilized with 1 N NaOH, and collected in glass culture tube
followed by measurement in a gamma counter (PerkinElmer) for 10 min. Non-specific binding
(usually less than 1 % of specific binding) was determined by replacing 125I-hormone with
excessively higher concentrations of hormone. Kd values and number of receptors were
determined by Scatchard plots.
Radioimmunoassay for Flag-LHR
Flag-LHR was prepared by inserting the Flag epitope, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (5GAC TAC AAG GAC GAT GAC GAT AAG-3), between the C terminus of the signal sequence
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and the N terminus of mature receptors. Mouse anti-Flag monoclonal M2 antibody (Sigma) was
iodinated with 125I according to the published procedure for radio-iodination of hCG (65), and
125

I-anti-Flag antibodies were purified on a Sephadex G-150 column. Binding of 125I-anti-Flag

(150,000 cpm) to HEK 293 cells expressing Flag-LHRs was carried out in the presence of
increasing concentrations of non-radioactive anti-Flag antibody in MEM containing 3 mg/ml of
bovine serum albumin for 8-10 h at 4 °C. 125I-anti-Flag antibody (65) was used to determine the
concentrations of receptors incapable of binding the hormone, in comparison with 125I-hCG used
to determine the concentration of receptors capable of binding the hormone.
Results
To investigate the interaction of heterozygous mutant LHRs, we chose the K583R mutant
(LHRK583R) in which Lys583 was substituted with Arg. This mutant receptor is normally
processed and targeted to the cell surface and is capable of binding hCG but incapable of
inducing cAMP production (45). The mutant receptor is referred to as LHR+hCG/-cAMP. In addition
to the LHR+hCG/-cAMP, other mutant LHRs were selected that were expressed on the cell surface
but were incapable of binding hCG (LHR-hCG). They are L20A, C22A, P479A, and P479G mutants
(21, 66). HEK 293 cells transiently transfected with the LHRK583R plasmid showed hCG binding
with the wild type affinity but did not produce cAMP in response to increasing doses of hCG
(Figure 2.1). Cells transiently transfected with the plasmid for LHRL20A, LHRC22A LHRP479A, or
LHRP479G did not show hCG binding or cAMP induction, consistent with previous reports (21,
66). The cells transfected with the blank plasmid, pcDNA3, failed to bind hCG and produce
cAMP, indicating that the vector itself was not involved in hCG binding.
Next, cells were co-transfected with a pair of LHR+hCG/-cAMP and LHR-hCG, for example, K583R
and L20A mutants or K583R and C22A mutants. The cells that were co-transfected with either
LHRK583R and LHRL20A or LHRK583R and LHRC22A were capable of binding hCG, and the Kd
values were similar to the wild type value (Figure 2.2, A and B). In addition, these cells induced
cAMP production in an hCG dose-dependent manner (Figure 2.2, C). The maximal levels of
cAMP were approximately one-third of the wild type value, and their EC50 values were 15-25-
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fold higher than the wild type value (Figure 2.2, table), suggesting the rescue of cAMP induction
with lower potency.
The data shown in Figure 2.2 suggest that the non-binding receptors were expressed on the cell
surface, as rigorously demonstrated by different methods in previous reports (21, 66). However,
to validate the surface expression, cells were transfected with the mutant receptors that carry the
Flag epitope at the N terminus (Flag-LHRC22A) and assayed for binding of anti-Flag monoclonal
antibody as described previously (21, 26). The cells were incubated with 125I-anti-Flag
monoclonal antibody with increasing concentrations of non-radioactive antibody. The cells
showed specific binding of the 125I-antibody, which was gradually displaced by non-radioactive
antibody, as did the cells transfected with Flag-LHRWT (Table 2.2). However, there was no
specific antibody binding to the cells transfected with the LHRWT, LHRC22A, or LHRL20A plasmid
as previously reported (21). These results show that the Flag-LHRs were indeed expressed on the
cell surface in these experiments. To determine whether Flag-LHRC22A can rescue cAMP
induction, it was coexpressed with LHRK583R. As expected, the cells bound hCG and produced
cAMP (Figure 2.3).
It is unclear whether cAMP was induced by accidental collisions between the endodomains of
two different mutant receptors. To test this possibility, several pairs of two different LHR-hCG
mutants were coexpressed. As shown in Figure 2.4, none of the coexpressed pairs (LHRC22A and
LHRL20A, LHRC22A and LHRP479A, LHRC22A and LHRP479G, LHRL20A and LHRP479A, and LHRL20A
and LHRP479G) was capable of inducing cAMP or binding hCG. These results show that one of
the mutant pairs has to be capable of binding hCG to rescue cAMP induction.
To test the dependence of the rescue on hCG binding, cells were co-transfected with varying
concentrations (6, 12, and 18 µg) of the LHRK583R plasmid and a constant amount (6 µg) of the
LHRL20A or LHRC22A plasmid. The cells were assayed first for hCG binding to determine the
relationship of the surface concentration of LHRK583R with the plasmid concentration (Figure 2.5).
The results show that the surface concentration of LHRK583R increased in parallel to the plasmid
concentration used for transfection. The range of the LHRK583R concentration was 5,000-21,000
receptors/cell, which compares favorably with the in vivo LHR concentration on porcine
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granulosa cells and rat Leydig cells, several thousand per cell (15-17). In addition, the variation
in the receptor concentration does not appear to impact the hormone binding affinity. However,
the maximum cAMP levels show an interesting trend. When 6 µg of the LHRL20A plasmid was
co-transfected with 6, 12, or 18 µg of the LHRK583R plasmid, the maximum cAMP levels were
52.4, 71.1, and 36.5 fmol/1000 cells, respectively. The differences among the three values are
statistically significant with p values of <0.05 to <0.001. Therefore, the maximum cAMP level
increased by 36% at 12 µg and then decreased by 30% at 18 µg as compared with the cAMP
level at 6 µg of the plasmid. The result was similar when 6 µg of the LHRC22A plasmid was cotransfected with 6, 12, or 18 µg of the LHRK583R plasmid. These observations suggest that the
cAMP rescue requires LHRK583R and is dependent on the concentration of this mutant receptor.
One may question whether the surface expression levels of the LHR-hCG mutants shown in Figure
2.5 were constant, although 6 µg of the plasmids was used for transfection of the cells throughout
the experiment. To address this problem, we took another approach to keep the expression level
of LHR-hCG mutants constant. Cell lines were established after stably transfecting them with the
LHRL20A plasmid or LHRC22A plasmid. These cell lines were transfected again with varying
concentrations (6, 12, and 18 µg) of the LHRK583R plasmid. The doubly transfected cells showed
increasing concentrations of LHRK583R (Figure 2.6). Transfection with 12 µg of the LHRK583R
plasmid increased the maximum cAMP level by 29-58% over that of the cells transfected with
6 µg of the plasmid. Transfection with 18 µg of the plasmid resulted in a 3-fold increase in the
EC50 value for the cAMP rescue, although the maximum cAMP levels remained high. The
observations described in Figures 2.6 and 2.7 indicate that the cAMP rescue is dependent on the
LHRK583R concentration. However, there is a notable difference in the results of Figures 2.6 and
2.7. In Figure 2.5 the maximum levels of cAMP peaked as the LHRK583R concentration increased,
whereas it plateaued in Figure 2.6. The difference in the two experiments was LHR-hCG, which
was transiently expressed in the Figure 2.5 experiment and stably expressed in the Figure 2.6
experiment. A molecule is expressed in stable cell lines generally more than in transiently
expressing cells because of the associated antibiotic selection. Therefore, another experiment was
performed using the stable cell line expressing Flag-LHRC22A, which appears to express less than
12,800 receptors/cell. It was transiently transfected with increasing concentrations of the
LHRK583R plasmid from 3 to 18 µg. The cells produced cAMP in response to hCG, and the
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maximum cAMP levels peaked (Figure 2.3). These results taken together with the data shown in
Figures 2.6 and 2.7 show that there are optimal concentrations of LHRK583R to pair with LHR-hCG
and rescue cAMP induction. They indicate the importance of the number of the hCG binding
receptor and/or the ratio of the hCG binding receptor to the non-binding receptor.
The non-binding receptors tested so far have mutations in the exodomain that impair hormone
binding. In addition to these non-binding receptors with a defective exodomain, there are nonbinding receptors that have a normal exodomain but mutation in the endodomain, such as P479A
and P479G of the transmembrane helix 4 (66). These mutations in the endodomain block hCG
binding to the exodomain by constraining the exodomain although the exodomain itself is intact
(33, 34). To test whether these mutants could pair with LHRK583R and induce cAMP production,
LHRK583R was coexpressed with LHRP479A or LHRP479A. The cells co-expressing LHRK583R and
LHRP479A or LHRK583R and LHRP479A failed to induce cAMP production although they were
capable of binding hCG (Figure 2.6). These results indicate that not all of the mutant pairs of
LHR-hCG and LHR+hCG/-cAMP are capable of rescuing the hCG dependent cAMP induction,
suggesting a specificity for pairing. Furthermore, these results suggest that LHR-hCG with a
mutation in the exodomain, but not in the endodomain, could be rescued.
In addition, we tested the affect of another receptor species on the activity of wild type LHR.
When LHRWT was coexpressed with FSHRWT, the functional FSHR did not impact the hCG
binding affinity or the EC50 value and maximum level of cAMP induction by LHRWT (Figure
2.8). These results show that the cAMP induction by LHR-hCG and LHR+hCG/-cAMP was not
rescued by accidental collisions between them or with different hormone receptor species.
Discussion
The observations described in this dissertation show that cells co-expressing a pair of two
differently defective mutants, one defective in hCG binding at the exodomain (LHR-hCG) and the
other defective in signal generation at the endodomain (LHR+hCG/-cAMP), can induce cAMP
production. This successful rescue of cAMP induction requires both types of mutant receptors.
However, not all LHR-hCG were capable of pairing with LHRK583R, an LHR+hCG/-cAMP, and
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rescuing cAMP induction. Rescue is observed when hormone binding of an LHR-hCG is impaired
by a mutation in the exodomain but not by mutations in the endodomain. These results suggest
specificity for the rescue of cAMP induction. For example, the rescue is dependent on hCG dose,
the surface concentration of the mutant receptors, and the amino acid positions of the mutations.
Furthermore, random collisions among mutant receptors are not involved in the rescue.
It is known that LHR binds hCG first at the exodomain (9, 19, 67), and the resulting hCGexodomain complex undergoes conformational changes (68-70) and modulates the endodomain
(29, 30). This secondary interaction is responsible for signal generation and receptor activation (7,
62, 63). Based on these observations and the results described in this dissertation, the cooperation
between the two types of mutant LHRs includes the exodomain of LHRK583R and the endodomain
of LHRL20A or LHRC22A. Furthermore, the two domains most likely interact with each other.
Therefore, the results suggest an intermolecular interaction (trans-activation) between the
exodomain of one receptor and the endodomain of another receptor and implicate at least partial
substitution of the hCG-functional exodomain complex of a receptor for the defective exodomain
of another receptor. This is appealing if LHR form dimmers. In a dimeric situation, a liganded
LHR could cis-activate itself and then, trans-activate its partner LHR in the dimmer. However,
the existing crosslinking and immunological evidence do not support oligomerization of LHRs.
The intermolecular exodomain-endodomain interaction is also consistent with the dependence of
the rescue on receptor concentrations and the existence of optimal concentrations. The
observation that too few or too many LHR+hCG/-cAMP can interfere with the collaboration between
LHR+hCG/-cAMP and LHR-hCG is of interest and reminiscent of the antibody and antigen interaction.
Too many LHR+hCG/-cAMP would nonproductively compete for a limited number of LHR-hCG,
which could lead to less effective induction of cAMP.
Previous studies on the dose-response relationship between hCG binding and hCG-stimulated
cAMP and steroidogenesis indicate that cellular responses, such as testosterone synthesis in
Leydig cells, reach their maximum at very low hormone concentrations and had no effect upon
cAMP production (15, 71, 72). Hormone occupancy of only 1-3% of the receptor sites was
enough to induce maximum steroidogenesis, and specific hormone binding was undetectable at
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these low hormone concentrations (1-2 pM) (15). The EC50 of cAMP induction (50 pM) was ten
times lower than the EC50 of hCG bound (500-600 pM) (15). The presence of these > 97%
“unbound” receptors are referred to as "spare receptors". The term does not imply that these
receptors are not utilized; rather, a maximum biological response is achieved when 1-3% of
receptors are occupied. The importance of these spare receptors is that they compensate for low
concentrations of hormone in physiological conditions and remove excess hormones soon after
hormone action, a necessary step. When the spare receptor number decreases, the EC50 for
cAMP induction increases, requiring more hormone for the same maximal cAMP induction (73).
The difference of hCG concentrations required for half-maximal cAMP production and halfmaximal occupancy of receptor sites, along with the absence of direct evidence of increased
adenylyl cyclase activity during stimulation of steroidogenesis by low hCG concentrations have
raised the possibility that other membrane-associated responses may be involved during the
initial phase of gonadotropin-induced steroidogenesis in the Leydig cell (15, 74). The data from
this dissertation suggests the intriguing possibility of intermolecular trans-activation of other
unoccupied LHRs by a liganded LHR, in addition to intramolecular cis-activation of its own
endodomain. It is tempting to speculate that pleiotropic trans-activation of the LHRs might lead
to maximum steroidogenesis with hormone occupancy on 1% of the receptor sites.
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Table 2.1

Surface expression of Flag-LHRs

Cells were transfected with various Flag-LHR plasmids and assayed for 125I-monoclonal anti
Flag-antibody binding in the presence of increasing concentrations of unlabeled antibody as
described under "Materials and Methods." Specific antibody bindings were determined and
compared with the specific binding of the Flag-LHRWT.
125

I-anti-Flag mAb
Binding (%)

LHRWT

5±3
WT

Flag-LHR

100 ± 9

Flag-LHRL20A

91 ± 17

Flag-LHRC22A

60 ± 15
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Figure 2.1 Activity of mutant receptors. HEK 293 cells were transiently transfected with
pcDNA3, a eukaryotic expression vector, or the vector with the wild-type LHR and various
mutants. The cells were assayed for 125I-hCG binding in the presence of increasing
concentrations of unlabeled hCG (A). The results were converted to Scatchard plots (B). In
addition, the cells were treated with increasing concentrations of unlabeled hCG, and
intracellular cAMP was measured (C) as described under "Materials and Methods." The
experiments were performed in duplicate and repeated three to four time (n=6-8). The means and
standard deviations are presented in the table (below panels A-C). NS, not significant.
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Figure 2.2 Coexpression of LHR-hCG and LHR+hCG/-cAMP. HEK 293 cells were transiently
coexpressed with an LHR defective in hCG binding and an LHR defective in cAMP induction
and were assayed for hCG binding and cAMP induction as described in the legend for Figure 2.1.
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Figure 2.3 Coexpression of Flag-LHRC22A and LHRK583R. Cells stably expressing FlagLHRC22A were transfected with increasing concentrations of the LHRK583R plasmid. The cells
were assayed for hormone binding and cAMP induction as described in the legend for Figure 2.1.
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Figure 2.4 Specificity of cAMP rescue. Cells were transiently coexpressed with various
combinations of LHR-hCG and assayed for hormone binding and cAMP induction as described in
the legend for Figure 2.1.
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Figure 2.5 Receptor concentration-dependent cAMP rescue. Cells were transiently
cotransfected with varying concentrations of the LHRK583R plasmid and 6 µg of the LHRC22A or
LHRL20A plasmid. The cells were assayed for hormone binding and cAMP production as
described in the legend for Figure 2.1.
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Figure 2.6 Coexpression of stable LHR-hCG and transient LHR+hCG/-cAMP. Cells stably
expressing LHR-hCG were transiently transfected with increasing concentrations of the LHRK583R
plasmid. The cells were assayed for hormone binding and cAMP production as described in the
legend for Figure 2.1.
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Figure 2.7 cAMP rescue is dependent on the location of mutation in LHR-hCG. Cells were
transiently coexpressed with LHRK583R and LHRP479A or LHRK583R and LHRP479G. The cells were
assayed for hormone binding and cAMP production as described in the legend for Figure 2.1.
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Figure 2.8 Coexpression of LHRWT and FSHRWT. 12 µg of FSH receptor plasmid was
transiently transfected into HEK 293 cells stably expressing LHRs. The cells were assayed for
hormone binding and cAMP production as described in the legend for Figure 2.1.
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Chapter 3

No Trans-activation of the LHR for IP Signaling

Introduction
Many hormone receptors, including those for glycoprotein hormones, activate multiple
intracellular signals such as cAMP, inositol phosphate, and Ca2+ through their promiscuous
couplings to diverse G proteins. It has been known since the 1970s that cAMP is released by rat
Leydig cells during gonadotropin stimulation (71, 75), and thereafter cAMP has been recognized
as a primary second messenger of LH action in the theca and granulosa cells and in the corpus
luteum (52). A decade later it became known that the LH also affects phosphoinositide
metabolism in rat granulosa cells (76). The LHR was reported to be dually coupled to adenylyl
cyclase and phospholipase Cβ (77). Gs and Gi were revealed to activate adenylyl cyclase and
phospholipase Cβ, respectively, upon hormone stimulation (78, 79). It was further identified that
the LHR activates phospholipase Cβ via preferential coupling to Gi2 (44), although
phospholipase Cβ stimulation is considered to generally be activated by the βγ subunit (80).
Though the cellular responses by the LHR are mediated by both adenylyl cyclase and
phospholipase Cβ, the LHR preferentially activates adenylyl cyclase with 100-fold lower EC50
than the activation of phospholipase Cβ (17). LH is responsible for the final maturation of the
ovarian follicles and estrogen secretion (81). It is also responsible for ovulation, the initial
formation of the corpus luteum, and secretion of progesterone (81). Intracellular cAMP is known
to be mainly responsible for the expression of specific genes involved in the LH action (81).
The physiological role of the phospholipase Cβ pathway is not clearly defined yet. The
activation of phospholipase Cβ by the LHR requires high hormone concentrations (EC50: 1-10
nM) and large receptor numbers (17, 46, 82) compared with the activation of adenylyl cyclase.
This suggests that the phospholipase Cβ pathway exists in granulosa cells in females. However,
one wonders whether it is active in Leydig cells, because the hCG/LH concentrations are
generally below the EC50 values. A study on the impairment of ovulation in rats with PKC
inhibitors supports the role of the phospholipase Cβ pathway in ovulation (83). These three
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signaling pathways, cAMP, inositol phosphate, and protein kinase C, stimulated by the LHR
have been reported to be independent of each other. Pretreatment with a physiological activator
of protein kinase C, PGF2α, had no effect on LH-stimulated inositol phosphate accumulation
(84), and neither forskolin nor prostaglandin E1, which both increase cAMP levels in L cells, had
an effect on inositol phosphate accumulation and Ca2+ elevation in L cells (17).
Another clue in the role of the inositol phosphate signaling from the LHR comes from a clinical
LHR mutant (Asp578His) causing Leydig cell tumors (85). This mutation is located in the TM6
(Figure 1.6). Normally, hormone-mediated activation of the LHR in Leydig cells does not result
in the stimulation of the phospholipase Cβ pathway due to the absence of high concentrations of
LH, unlike in granulosa cells (5). The main feature that distinguishes the Asp578His mutation
from other LHR Asp578 mutations associated with male-limited precocious puberty is its ability
to elevate both the basal cAMP and IP levels in the absence of hormone (85). Other LHR
mutants such as Asp578 to Gly, Leu, Pro, and Tyr, constitutively activate only cAMP signaling
pathway (47). The different clinical phenotype of Leydig cell adenoma by the LHR Asp578His
mutation suggests distinct physiological functions of adenylyl cyclase and phospholipase Cβ
pathways in LH signaling and also suggests the role of the phospholipase Cβ signal.
It has been demonstrated that trans-activation of LHRs lead to the activation of adenylyl cyclase
to induce cAMP in the previous studies (42, 43). We wondered whether the trans-activation of
the LHR also leads to the activation of phospholipase Cβ. It is an intriguing question in regard to
multiple hormonal signal generation because the LHR activates both adenylyl cyclase and
phospholipase Cβ, but they require different hormone concentrations.
The LHR-hCG and LHR+hCG/-IP mutants were utilized to elucidate the possibility of inositol
phosphate signaling rescue by trans-activation of the LHR. A strategy of transient expression of
two defective LHRs in HEK 293 cells, which at the same condition successfully rescued cAMP
signaling, was used with high hCG concentrations of up to 1-10 µM. Also HEK 293 cells stably
expressing both defective LHRs were established to facilitate high cell surface expression and
assayed for the rescue of inositol phosphate signaling.
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Materials and Methods
Inositol Phosphate Assay-- Stable cells were plated in 12-well plates and grown in inositol-free
Dulbecco's modified Eagle's medium (Atlanta Biologicals) supplemented with 8% heatinactivated horse serum and 2 µCi/ml [3H]inositol (PerkinElmer Life Sciences) for 48 h to 4050% confluency. After removing the medium, the cells were incubated in 1 ml of fresh wash
buffer consisting of Dulbecco's modified Eagle's medium without inositol and 15 mM HEPES
(pH 7.3) for 1 h at 37 °C. This medium was removed, and 0.3 ml of wash buffer containing
20 mM LiCl was added and incubated for 15 min at 37 °C. After the cells were stimulated with
increasing concentrations of hormone for 30 min at 37 °C, the incubation was terminated by the
removal of medium and the addition of 0.25 ml of 0.6 N HCl to each well. The cells were scraped
and transferred into microcentrifuge tubes, and the wells were again washed with 0.25 ml of
0.6 N HCl. The combined washes were treated with 0.9 ml of a mixture of chloroform:methanol
(2:1), vortexed, and centrifuged at 1000 × g for 5 min at room temperature. The top aqueous
layer, which was free of phospholipids, was removed, and the remaining chloroform layer was
treated with 0.2 ml of methanol:water (1:1), vortexed, and centrifuged, as above. This aqueous
layer was added to the previous aqueous layer, and the samples were dried in a vacuum
concentrator. The dried samples were redissolved in 0.5 ml of 50 mM Tris-HCl, pH 8, and
applied to Dowex AG 1-X8 formate (Bio-Rad) columns. The microcentrifuge tubes were washed
twice with 0.5 ml of the same buffer, and the washes were applied to the columns for a total of
1.5 ml. The columns were sequentially washed with 4.5 ml of H2O and 4.5 ml of 60 mM
ammonium formate and 5 mM sodium tetraborate to elute the free inositol and the glycerol
phosphatidylinositol, respectively. IP1, IP2, and IP3 were sequentially eluted with 4 ml of 0.1 N
formic acid in 0.2, 0.75, and 1.1 M ammonium formate, respectively, and collected in 1-ml
fractions. Aliquots of 200 µl were counted for radioactivity in 1.5 ml of Ultima AF scintillation
fluid (Packard). Peak radioactivities were used for the data analysis.
Hormone binding assay and intracellular cAMP assay procedures are same as described in
"Materials and Methods" of the Chapter 2.
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Results
Mutant LHRs used to successfully rescue cAMP induction in Chapter 2 and in our previous
publications (42, 43) were selected to determine whether or not the rescuing of cAMP signaling
by trans-activation of LHRs would also activate phospholipase Cβ and IP signaling. The nonbinding LHRs were L20A, C22A, I55A, and I80A (LHR-hCG). LHRs defective in signaling were
K583R and ExoCD (LHR+hCG/-cAMP/-IP). The ExoCD is a chimera with a functional LHR
exodomain linked to the non-functional CD 8 transmembrane and cytoplasmic domain (86)
(Figure 3.1). HEK 293 cells stably expressing these mutant LHRs were established, and the
induction of inositol phosphate was measured in the presence of hCG (Figure 3.2). None of these
mutant LHRs showed any elevated basal level. IP subspecies (IP1, IP2, and IP3) were also
measured but failed to show any increase.
Studies on IP induction by the LHR have revealed that two conditions are required: high hCG
concentrations and large receptor numbers (17, 46). To check this, HEK 293 cells stably
expressing wild type LHRs were established. Transfection studies showed that IP induction
required high receptor concentrations on the cell surface (Figure 3.3). Cells stably expressing
receptors usually show high receptor expression due to antibiotic selection (> 140,000
receptor/cell in this study). However, cells transiently transfected with 12 µg of LHR plasmid
show about 12,000 receptors per cell. The data in the Figure 3.3 shows that IP induction is also
dependent on receptor concentrations. Net cpm increase of IP induction in stable cells is 4-5 fold
higher than that in cells transiently expressing the receptors. To study whether those mutant LHR
combinations which successfully rescued cAMP induction in the previous chapter, in
physiological range of receptor numbers (6,000 – 20,000 receptors/cell), also rescues IP
induction, the same transient transfection method was utilized. Also HEK 293 cells stably
expressing both mutant receptors were selected and assayed for IP induction.
First, 12 µg of LHRK583R were transiently transfected into HEK 293 cells with 6 µg each of
LHRL20A, LHRC22A, LHRI55A, and LHRI80A. Trans-activation between the two receptors rescued
cAMP induction up to 27-41% of the max cAMP induction by wild type LHR but failed to
induce IP production (Figure 3.4). IP subspecies (IP1, IP2, and IP3) induction was also measured
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but none was found. Our group showed that ExoCD had slightly higher cAMP induction than
LHRK583R when coexpressed with non-binding LHRs (43). Thus, ExoCD was coexpressed with
LHRL20A, LHRC22A, LHRI55A, or LHRI80A transiently in HEK 293 cells (Figure 3.5). Up to 10 µM
of hCG was added to see whether this extremely high concentration of hormone stimulates LHRs
for IP induction. However, no induction of IP signaling including IP1, IP2, and IP3 was seen.
Next, HEK 293 cells stably expressing LHRL20A or LHRC22A were transiently transfected with
increasing concentrations of LHRK583R plasmids (6 to 18 µg) (Figure 3.6), but there was no IP
induction, contrary to the successful cAMP induction. HEK 293 cells stably expressing
LHRK583R were also established, and LHRL20A or LHRC22A was transiently transfected, but there
was no IP induction.
To make sure two defective LHRs are expressed in HEK 293 cells in high concentrations, HEK
293 cells stably expressing ExoCD and LHRI55A were established and selected by G-418. hCG
binding to cell surface ExoCD showed more than 130,000 receptors/cell, but there was no IP
induction (Figure 3.7). In addition to this, another HEK 293 cell line stably expressing ExoCD
and LHRI80A was also established and assayed for IP signaling but failed to induce any IP
production. These HEK 293 cells had two mutant LHRs in the same G-418 resistance vector.
Though they rescued cAMP signaling very successfully in the previous chapter, there was a
chance that these cells used for IP rescuing might not have had both receptors on the cell surface.
To ensure the expression of both mutant receptors, another stable HEK 293 cell line expressing
both receptors with different antibiotic selection was established. Even with ExoCD in the
hygromycin B resistance vector and LHRI55A or LHRI80A in the G-418 resistance vector, there
was again no IP induction (data not shown).
LHRP479A or LHRP479G did not induce cAMP in the previous chapter when they were coexpressed
with LHRK583R. However, it is still possible that they may rescue IP induction by a different
trans-activation mechanism. To test this possibility, LHRP479A or LHRP479G was coexpressed with
LHRK583R transiently in HEK 293 cells and assayed for IP induction. No IP induction was
observed up to 1 µM of hCG concentration (Figure 3.8).
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The absence of IP induction from the stably and transiently coexpressed pairs of LHRs which
successfully rescued cAMP signaling suggest the possibility that mutant LHRs might had
impaired the G proteins associated with the IP signaling. LHRWT was coexpressed with LHRI80A
and with LHRI80A and LHRK583R, but the coexpressed of mutant LHR(s) did not affect IP
induction of the wild type LHR (Figure 3.9), suggesting the absence of IP induction is not due to
the impairment of G proteins by mutant LHRs.
Discussion
The results described in this chapter show that a liganded LHR exodomain was capable of transactivating the endodomain of some unliganded LHRs and stimulating adenylyl cyclase but not
for phospholipase Cβ. These observations suggest that cis-activation of LHR stimulates both
adenylyl cyclase and phospholipase Cβ, whereas trans-activation of LHR is limited to adenylyl
cyclase. Therefore, the modulation of the endodomain by the exodomain during trans-activation
is likely limited. Our group showed that mutations at downstream of the N-terminal region,
L103A, I105A, L179A, and L202A do not allow trans-activation (43). A simple explanation is that
the location of non-binding mutations plays a role in trans-activation. The non-binding mutations
in the N-terminal region are permissible for trans-activation, whereas the non-binding mutations
downstream of N-terminal region are not. Interestingly, some amino acids residues in this nonpermissible region are involved in modulating the endodomain and the signal generation. S255 of
LHR suppresses the endodomain (30) and G91 of LHR activates it (26). These residues are
conserved in the FSH, LH, and TSH receptor. Furthermore, there is evidence that these regions
make contacts with the endodomain (28, 36). Since the hormones also interact with the
exodomain and endodomain, it is likely that the interactions among the hormone, exodomain,
and the endodomain differ in trans-activation and cis-activation. The interactions appear to be
more restricted in trans-activation.
The absence of IP induction by LHR trans-activation provides a clue to our understanding of
100-fold higher EC50 of IP production compared to cAMP production. Trans-activation provides
a mechanism of hormone signal amplification at the receptor level as was demonstrated by
cAMP rescuing, thus the LHR could achieve maximal cAMP induction at low hormone
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concentrations, but this was not seen with IP signaling. The IP signaling pathway only seems to
be mediated by cis-activation, which requires more hormones for phospholipase Cβ activation.
Another possibility for the lack of IP induction by the trans-activation of the LHR might be due
to low affinity of Gi2 to the LHR compared to that of Gs. It has not been determined how much
Gs and Gi2 are endogenously expressed in HEK 293 cells. Future study including overexpression
of Gi2 in HEK 293 cells with coexpression of two defective heterozygous LHRs will help to
elucidate whether the lack of IP induction is due to more restriction of hormone-receptor contacts
in trans-activation than in cAMP induction or to low affinities of Gi2 to the LHR.
It has been an enigma as to how a hormone receptor can generate two or more signals, such as
LHR being capable of activating two enzymes, adenylyl cyclase and phospholipase Cβ.
Particularly, it is unclear whether one receptor molecule can generate only one signal or two
distinct signals at a time. If the former is the case, cis- and trans-activation provide a mechanism
for generation of two signals by one receptor. For example, a liganded LHR could cis-activate
itself to stimulate phospholipase Cβ and trans-activate another LHR to stimulate adenylyl
cyclase. This mechanism would allow one liganded receptor to generate multiple signals without
a receptor simultaneously interacting with multiple G proteins.

Copyright © ChangWoo Lee 2003
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Table 3.1

Surface expression of Flag-LHRs

Cells were transfected with various Flag-LHR plasmids and assayed for 125I-monoclonal anti
Flag-antibody binding in the presence of increasing concentrations of unlabeled antibody as
described under "Materials and Methods." Specific antibody bindings were determined and
compared with the specific binding of the Flag-LHRWT.
125

I-anti-Flag mAb
Binding (%)

LHRWT

5±3

Flag-LHRWT

100 ± 9

Flag-LHRC22A

25 ± 3

Flag-LHRI55A

33 ± 5

Flag-LHRI80A

30 ± 5
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Figure 3.1 Will there be trans-activation of LHR for inositol phosphate signaling? A.
Domain structure of LHR showing the exodomain where the ligand binds and the endodomain
where the hormone signal is generated. B. Cis- and trans-activation of monomeric LHRs. Transactivation of the LHR generates cAMP signaling. The ligand is shown in red. C. Hypothesis of
trans-activation of a non-binding mutant LHR (LHR-hCG/+IP) by a mutant LHR that is capable of
hormone binding but defective in signal generation (LHR+hCG/-IP) Normal parts are shown in gray
and defective parts are shown in blue. D. Hypothesis of trans-activation of a mutant LHR (LHRhCG/+IP
) by a chimera with a functional LHR exodomain linked to the non-functional CD 8
transmembrane and cytoplasmic domain (ExoCD). Normal parts are shown in gray and defective
parts are shown in blue.
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Figure 3.2 Activity of mutant receptors. HEK 293 cells stably expressing wild-type or mutant
LHRs were established by transfecting each with 12 µg of receptor plasmid followed by G-418
selection. The cells were assayed for 125I-hCG binding in the presence of increasing
concentrations of unlabeled hCG (A). In addition, the cells were treated with increasing
concentrations of unlabeled hCG, and intracellular cAMP (B) and inositol phosphates including
inositol mono- (IP1), bis- (IP2), and tris-phosphates (IP3) (C) were measured as described under
"Materials and Methods." The experiments were performed in duplicate and repeated three to
four time (n=6-8). The means and standard deviations are presented in the table (below panels AC). NS, not significant.
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Figure 3.3 Induction of inositol phosphates from LHRWT. HEK 293 cells either stably or
transiently expressing LHRWT were established. The cells were assayed for intracellular inositol
phosphates (IP1, IP2, and IP3) induction in response to hCG as described in the legend for Figure
3.2.
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Figure 3.4 Coexpression of LHRK583R and LHR-hCG. 12 µg of LHRK583R plasmid was
cotransfected into HEK 293 cells with 6 µg of various mutant LHR plasmid, respectively. The
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as
described in the legend for Figure 3.2.
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Figure 3.5 Coexpression of ExoCD and LHR-hCG. 12 µg of ExoCD plasmid was
cotransfected into HEK 293 cells with 6 µg of various mutant LHR plasmid, respectively. The
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as
described in the legend for Figure 3.2.
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Figure 3.6 Coexpression of stable LHR and transient LHR. HEK 293 cells expressing stable
LHR+hCG/-cAMP and transient LHR-hCG, or vice versa, were assayed for hormone binding and
intracellular cAMP and IP induction in response to hCG, as described in the legend for Figure
3.2.
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Figure 3.7 Coexpression of stable ExoCD and stable LHR-hCG. 6 µg of ExoCD plasmid and
6 µg of various LHR-hCG plasmid was transfected into HEK 293 cells followed by G-418
selection. The cells were assayed for hormone binding and cAMP and IP induction in response to
hCG, as described in the legend for Figure 3.2.
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Figure 3.8 Coexpression of LHRK583R and TM4 LHR-hCG. 12 µg of LHRK583R plasmid was
co-transfected with 6 µg of LHRP479A or LHRP479G plasmid in HEK 293 cells, respectively. The
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as
described in the legend for Figure 3.2.
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Figure 3.9 Coexpression of LHRWT with LHR-hCG and LHR+hCG/-cAMP. LHRI80A with
pcDNA3 vector and LHRI80A with LHRK583R plasmids were transiently transfected into HEK 293
cells stably expressing LHRWT. The cells were assayed for IP induction in response to hCG, as
described in the legend for Figure 3.2.
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Chapter 4

Overlapping G Protein Binding Sites of the LHR

Introduction
Ligand/hormone binding to its cognate receptor leads to receptor activation and signal
transduction. Receptors for LH, FSH, and TSH belong to the G protein-coupled receptor (GPCR)
family and are unique in structure, possessing two halves of ~350 amino acids; the N-terminal
extracellular hormone binding exodomain and the C-terminal half endodomain including three
exoloops, seven transmembrane helices, and three cytoloops, responsible for signal generation
(7). Hormone binding to the high affinity exodomain leads to conformational changes in the
hormone/exodomain complex and modulates hormone signals from endodomain of the receptor,
especially through the exoloops (24). The LHR activates both adenylyl cyclase and
phospholipase Cβ to induce cAMP and inositol phosphate, respectively (17, 77). Our group
showed that certain amino acids in exoloops 2 and 3 of the LHR and FSHRs are critical for
hormone binding and signal generation (33, 34, 45), and the exoloop 3 of the FSHR physically
contacts with the exodomain (32, 46). Multiple hormonal signals of the LHR and FSHR are
distinct and considered to be generated at the exoloops (32, 46). Gudermann’s group and
Hunzicker-Dunn’s group showed the involvement of both Gs and Gi with the LHR in membranes
of bovine corpus luteum and L cells (78) and in porcine ovarian follicular membranes (87),
respectively. Gudermann’s group further identified that the LHR activates phospholipase C via
preferential coupling to Gi2 (44).
There are a small number of receptors that couple to G proteins for the activation of both
adenylyl cyclase and phospholipase Cβ. These include receptors for the LH (17), FSH (88), TSH
(89), GnRH (90), PACAP (91, 92), PTH (93), and calcitonin (94). Interestingly, all of these
receptors belong to a subfamily of GPCRs which recognize peptide hormones as their ligands.
An exception to this case is the P2Y11 receptor which has high affinity to the small nucleotide
ATP. The P2Y11 receptor is, however, more homologous to G protein-coupled peptide hormone
receptors than to receptors for structurally related small nucleotide ligands (95), and it also
preferentially couples to phospholipase Cβ compared to adenylyl cyclase (96), whereas other
peptide hormone receptors have preferential coupling to adenylyl cyclase. In addition to the G
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protein-coupled peptide hormone receptor subfamily, histamine receptor (97) and α2A-adrenergic
receptor (98) also activate both adenylyl cyclase and phospholipase Cβ.
Usually amino acids in the exoloops affect differential ligand signaling (46, 99), but certain
mutations in the transmembrane domain and cytoloop areas have been shown to affect multiple
signaling of receptors. Tyr601 (TM5) of the TSH receptor (100, 101) and Ser232 (cytoloop 3) of
the α2A-adrenergic receptor (98) serve as molecular switches to transduce cAMP and inositol
phosphate signaling selectively. Due to the location of these mutations near the receptor-G
protein coupling site, cytoloop 3, Tyr601 and Ser232 mutations are considered to affect structural
requirements of the receptors for proper G protein-coupling.
This dual and differential cAMP and inositol phosphate signaling of these G protein-coupled
receptors requires sophisticated cellular machinery along with G proteins, such as Gs, Gi, and/or
Gq, and effector molecules. For example, wild type H1 and H2 histamine receptors, when
expressed in human breast epithelial cells, produced inositol phosphate but failed to produce
cAMP, though both signaling pathways are functional in those cells (102).
Studies using carboxyl terminal minigene peptides of G proteins indicate that different G
proteins may have overlapping binding sites on the thrombin receptor (103) and the α1B- and
α2A-adrenergic receptors (104), but it has not yet been elucidated with the LHR. We studied this
dual G protein-coupling mechanism of the LHR using transient expressions of Gs, Gi, and their
carboxyl terminal peptides with wild type and mutant LHRs. A constitutively activating TM6
mutant LHR, LHRD578G, provides a valuable tool to study G protein interactions with the LHR
due to its elevated cAMP level in the absence of hormone (105). The D578G mutation is the most
common cause of male-limited precocious puberty (106).
The data presented in this dissertation demonstrate that coexpression of the Gi2 carboxyl terminal
region (Gi2CT) surprisingly enhanced cAMP induction from the mutant LHRD578G, whereas the
Gi2CT inhibited cAMP induction from the wild type LHR. Coexpression of Gi2 whole molecule
with LHRD578G completely inhibited elevated cAMP level of the LHRD578G in the absence of
hormone to the basal level of LHRWT, suggesting its application to the development of future
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therapeutics for the treatment of patients with Asp578 to Gly mutation. Coexpression of Gq or G12
with the LHRD578G did not affect agonist-dependent cAMP induction. The data suggests that the
LHR has overlapping binding sites for Gs and Gi2.
Materials and Methods
Mutagenesis and Functional Expression of Receptors and G proteins-- Mutant human LHRD578G
cDNA was prepared in a pSELECT vector using the non-polymerase chain reaction-based
Altered Sites Mutagenesis System (Promega), sequenced, and subcloned into pcDNA3
(Invitrogen) as described previously (107). After subcloning into pcDNA3, the mutant cDNA
was sequenced again. Human G proteins were purchased from Guthrie (Sayre, PA). The
carboxyl terminal G protein peptides were constructed using PCR. cDNAs encoding amino acids
288-380 (93 a.a.) of Gs (GsCT) and 280-355 (76 a.a.) of Gi2 (Gi2CT) were amplified from G
protein cDNAs in pcDNA3.1 and subcloned into BamHI/XbaI sites of a pcDNA3 containing
haemagglutinin epitope. 1:1 ratio of receptor (6 µg) and G protein plasmids (6 µg) were
transfected into human embryonic kidney (HEK) 293 cells by the calcium phosphate method (64).
Transiently transfected cells were assayed 60-72 h after transfection. All assays were carried out
in duplicate and repeated three to four times (n=6-8). Means and standard deviations were
calculated.
cAMP assay procedure is same as described in the "Materials and Methods" of the Chapter 2.
Results
Competition of GsCT with endogenous Gs -- To investigate the interaction of G proteins and the
LHR, first we transfected 6 µg of 93-amino acid GsCT plasmid with 6 µg of the wild type and
mutant LHR plasmids, respectively, in HEK 293 cells (Fig. 1). Our previous study on transient
expressions of the LHR in HEK 293 cells shows that 5,000-7,000 receptor/cell are expressed
with transfection of 6 µg of the LHR cDNA plasmid (42), which is consistent with LHR numbers
in physiological conditions (15, 16). Coexpression of GsCT competitively inhibited cAMP
induction from both LHRWT and LHRD578G, but this inhibition of cAMP by GsCT was not

55

complete (Figure 4.1). This data suggest that the 93-amino acid GsCT competes for binding to
the LHR with endogenous Gs molecules.
Enhancement of cAMP induction by Gi2CT -- Next, we transfected 76-amino acid Gi2CT plasmid
with LHRWT and LHRD578G, respectively, in HEK 293 cells (Figure 4.1). Coexpression of Gi2CT
inhibited cAMP induction from LHRWT, but when Gi2CT was coexpressed with LHRD578G, it
surprisingly increased already elevated cAMP level two fold and, plus enhanced hormoneinduced cAMP induction. These data suggest that upon Gi2CT binding to the cytoloop 3 and
other G protein-coupling sites on the LHR, there were structural changes, either allosterically or
non-allosterically, which facilitated Gs-coupling to the LHRD578G. The enhancement of cAMP
induction by coexpression of 76-amino acid Gi2CT with LHRD578G also suggests that the LHR
has different or overlapping binding sites for Gs and Gi2.
Gs increases basal cAMP level -- Although the carboxyl terminal region of Gs and Gi2 seems to
have overlapping binding sites on the LHR, it is unclear whether Gs or Gi2 whole molecules can
compete for binding to the same LHR. First, Gs was coexpressed with LHRWT and LHRD578G,
respectively, in HEK 293 cells (Figure 4.2). Gs facilitated basal cAMP level from both LHRWT
and LHRD578G, but as wild type and mutant LHRs are activated by hormone, both receptors
restored their normal cAMP induction curve, and the effect of Gs was minimal.
Inverse Agonism of Gi2 on LHRD578G -- We coexpressed the Gi2 whole molecule with LHRWT
and LHRD578G, respectively (Figure 4.2). When Gi2 was coexpressed with LHRD578G, it
completely inhibited its elevated basal and hormone-induced cAMP level down to the basal level
of LHRWT. As was suggested with enhancement of cAMP induction with Gi2CT, these data
suggest that LHRD578G has more exposed G protein binding sites than LHRWT, thus promoting
Gi2 binding. Also, Gi2 inhibited hormone-induced cAMP induction from LHRWT but did not
affect the basal cAMP level of LHRWT, suggesting that LHRWT keeps its basal cAMP level low.
We also transiently expressed Gs and Gi2, respectively, in HEK 293 cells stably expressing wild
type LHRs (> 100,000 receptors/cell). The effect of transient expression of Gs or Gi2 was small
compared to transient expression of both receptor and G proteins (data not shown). This
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indicates that there is a stoichiometric relationship of interactions between the LHR and G
proteins.
Discussion
The Asp578Gly mutation is the most common cause of male-limited precocious puberty. This
mutant LHR shows 4-7 fold increased cAMP basal level in the absence of hormone, but the
maximal cAMP induction reaches 70-80% of wild type LHR. Substitutions of Glu, Tyr, and His
for Asp578 were also found in patients. Inhibition of cAMP induction by coexpression of Gi2
suggests that Gi2 can work as an inverse agonist for the constitutively activating Asp578Gly
mutant LHR. In addition to the frequent mutations of Asp578 in the LHR, an activating mutation
of the FSHR bearing Asp567Gly mutation (TM6) was found in a hypophysectomized man (108).
This activating FSHR mutation has so far been the only case of activating mutation among
FSHR mutations, and like the activating mutations of the LHR with the corresponding amino
acid Asp578Gly, it had elevated cAMP level when transfected into COS-7 cells in the absence of
hormone. The findings from this study may be helpful to the development of future therapeutics
for the treatment of patients with activating mutations of the LH or FSHR.
Studies using the carboxyl terminal minigene peptides of G proteins suggest that G proteins may
have overlapping binding sites on the receptor. Hamm’s group showed that 13-amino acid
minigene peptides of different G protein carboxyl termini specifically inhibited the thrombin
receptor-G protein interactions (103). Luttrell’s group showed that an 83-amino acid peptide of
Gs carboxyl terminal region selectively inhibited Gs coupling without affecting Gi or Gq-coupled
phosphoinositide hydrolysis from the α1B- and α2A-adrenergic receptors (104). The use of this
relatively large 83-amino acid peptide suggests that Gs binding sites on the receptor may be
different or not too much overlapped with Gi or Gq binding sites (104). This observation is also
consistent with our data that a 73-amino acid Gi2CT facilitates Gs binding to the LHR enhancing
cAMP induction. Berlot showed that coexpression of a dominant-negative Gs with the calcitonin
receptor inhibited both cAMP and inositol phosphate signaling, suggesting Gs and Gq compete
for binding to the same receptor (109).
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Trans-activation of the LHRs lead to the activation of adenylyl cyclase to induce cAMP, but
failed to activate phospholipase Cβ to induce inositol phosphate. This raises an intriguing
possibility that a liganded LHR could cis-activate phospholipase Cβ and trans-activate adenylyl
cyclase simultaneously. Trans-activation of the LHR and the results on overlapping G protein
binding sites on the LHR from this study suggest a mechanism of simultaneous multiple G
protein activations, with activation one G protein at a time from a single LHR.

Copyright © ChangWoo Lee 2003
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Table 4.1

Effect of Gs, Gi2, and their carboxyl terminal peptides on the cAMP induction
of LHRWT and LHRD578G

cAMP induction
EC50 (nM)

Basal

Max

(fmol/1000 cells)

(fmol/1000 cells)

LHRWT + pcDNA3

0.21 ± 0.02

10.3 ± 1.1

157.2 ± 0.2

LHRWT + GsCT

0.32 ± 0.06

8.6 ± 0.4

79.6 ± 1.1

LHRWT + Gi2CT

0.72 ± 0.36

26.3 ± 2.8

60.5 ± 0.4

LHRWT + Gs

0.30 ± 0.24

42.7 ± 2.9

156.5 ± 12.9

LHRWT + Gi2

0.68 ± 0.22

10.9 ± 1.5

79.3 ± 16.8

LHRD578G + pcDNA3

0.48 ± 0.01

46.4 ± 6.6

122.5 ± 1.2

LHRD578G + GsCT

0.38 ± 0.18

33.5 ± 1.0

65.1 ± 2.5

LHRD578G + Gi2CT

0.88 ± 0.13

86.0 ± 1.3

167.3 ± 11.8

0.42 ± 0.08

79.0 ± 7.3

125.0 ± 0.1

NS

7.2 ± 0.6

7.9 ± 0.8

D578G

LHR

+ Gs

LHRD578G + Gi2
(NS: Not Significant)
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Figure 4.1 Effect of GsCT and Gi2CT on cAMP induction of LHRWT and LHRD578G. 6 µg
of LHR plasmid and 6 µg of GsCT or Gi2CT minigene plasmid were transfected into HEK 293
cells, respectively. 60-72 hours after transfection, cells were assayed for cAMP induction.
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Figure 4.2 Effect of Gs and Gi2 on cAMP induction of LHRWT and LHRD578G. 6 µg of LHR
plasmid and 6 µg of Gs or Gi2 plasmid were transfected into HEK 293 cells, respectively. 60-72
hours after transfection, cells were assayed for cAMP induction.
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